Filling an obvious gap in the scientific literature, this practice-oriented reference is the first to tie together the working knowledge of large
screening centers in the pharmaceutical and biotechnological field. It spans the entire fi eld of this emerging discipline, from compound
acquisition to collection optimization for specific purposes, to technology and quality control. In so doing, it applies two decades of expertise gathered by several large pharmaceutical companies to current and future challenges in high-throughput screening. With its treatment of libraries of small molecules as well as biobanks containing biomolecules, microorganisms and tissue samples, this reference is universally applicable for any molecular scientist involved in a large screening program.

Mark Wigglesworth manages the UK Lead Optimization area of Sample Management Technologies for GlaxoSmith-Kline. Over the past 10 years Mark has managed large and small compound stores, assay ready plate production and compound set provision, as well as interacting with many areas of drug discovery. Additionally, he has led several drug discovery programs and overseen multiple screening platforms providing structure activity relationship data within GlaxoSmithKline?s screening organizations.
Now a freelance business consultant, Terry Wood retired in 2011 as the manager of the Liquid Store Centre of Emphasis at Pfizer?s world-wide R&D department, based in Sandwich (UK). He has been involved in the high-throughput screening process for the whole of his 25 year career with Pfizer. This has given him a first hand and broad knowledge about the challenges and caveats of assay design, development and
prosecution. His prime responsibility focused on the management of Pfizer?s extensive compound file, using a range of automated systems for sample preparation, storage and delivery.